Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer in a phase III trial did ...

Tiragolumab missed the chance to prove a survival benefit in SKYSCRAPER-01 adding to previous trial failures for the ...

The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its primary end point of overall survival.

The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...

Low-dose CT scans can help improve lung cancer survival rates with minimal radiation and no invasive procedures.

A cancer treatment from Roche failed to improve survival in a major lung cancer study, a result that will stoke doubts about ...

In 2022, the Swiss pharma giant said SKYSCRAPER-01 failed to reach the co-primary goal of progression-free survival. The ...

Genentech announced that the Phase III SKYSCRAPER-01 study, which evaluated tiragolumab combined with Tecentriq (atezolizumab) versus ...

Immutep Ltd (AU:IMM) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At ...

Patients at the McGill University Health Centre (MUHC) are the first in Canada, and among the first in the world, to test the ...

Roche’s Phase III SKYSCRAPER-01 trial missed its primary endpoint, with tiragolumab combined with Tecentriq failing to ...